16α-Bromoepiandrosterone restores T helper cell type 1 activity and accelerates chemotherapy-induced bacterial clearance in a model of progressive pulmonary tuberculosis

Journal of Infectious Diseases

Volumn 191, Issue 2, 2005, Pages 299-306

  Hernández Pando, Rogelio ^a   Aguilar Leon, Diana ^a   Orozco, Hector ^a   Serrano, Alberto ^a   Ahlem, Clarence ^b   Trauger, Richard ^b   Schramm, Beatrix ^b   Reading, Chris ^b   Frincke, James ^b   Rook, Graham A W ^c  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b HollisEden Pharmaceuticals   (United States)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

16 ALPHA BROMOEPIANDROSTERONE; ANDROSTERONE DERIVATIVE; GAMMA INTERFERON; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 16 BROMOEPIANDROSTERONE; 16-BROMOEPIANDROSTERONE; ANDROSTERONE; DRUG DERIVATIVE; IMMUNOLOGICAL ADJUVANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVITY; CHEMOTHERAPY; CLEARANCE; LUNG TUBERCULOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; ADJUVANT CHEMOTHERAPY; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECT; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MYCOBACTERIUM TUBERCULOSIS; PATHOLOGY; URINE;

ADJUVANTS, IMMUNOLOGIC; ANDROSTERONE; ANIMALS; CHEMOTHERAPY, ADJUVANT; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; TH1 CELLS; TUBERCULOSIS, PULMONARY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 19944426355     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/426453     Document Type: Article

References (40)

1. + T cells in immunity to tuberculosis. Trends Microbiol 1993; 1:77-8.
2. Orme IM, Andersen P, Boom WH. T cell response to Mycobacterium tuberculosis. J Infect Dis 1993; 167:1481-97.
3. Stenger S, Hanson DA, Teitelbaum R, et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998; 282:121-5.
4. + T cells in purified protein derivative-positive, but not in purified protein derivative-negative subjects. J Immunol 1998; 160:2408-17.
5. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001; 345:1098-104.
6. Newport M, Huxley CM, Huston S, et al. A mutation in the interferon-γ receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996; 335:1941-9.
7. Yong AJ, Grange JM, Tee RD, et al. Total and anti-mycobacterial IgE levels in serum from patients with tuberculosis and leprosy. Tubercle 1989; 70:273-9.
8. Relloso M, Puig-Kroger A, Pello OM, et al. DC-SIGN (CD209) expression is IL-4 dependent and is negatively regulated by IFN, TGF-β, and anti-inflammatory agents. J Immunol 2002; 168:2634-43.
9. Fischer K, Collins H, Taniguchi M, Kaufmann SH, Schaible UE. IL-4 and T cells are required for the generation of IgG1 isotype antibodies against cardiolipin. J Immunol 2002; 168:2689-94.
10. Seah GT, Scott GM, Rook GA. Type 2 cytokine gene activation and its relationship to extent of disease in patients with tuberculosis. J Infect Dis 2000; 181:385-9.
11. Seah GT, Rook GAW. High levels of mRNA encoding IL-4 in unstimulated peripheral blood mononuclear cells from tuberculosis patients revealed by quantitative nested RT-PCR; correlations with serum IgE levels. Scand J Infect Dis 2001; 33:106-9.
12. + T cells from patients with tuberculosis is related to the presence of pulmonary cavities. J Infect Dis 2000; 181:1194-7.
13. Marchant A, Amedei A, Azzurri A, et al. Polarization of PPD-specific T-cell response of patients with tuberculosis from Th0 to Th1 profile after successful antimycobacterial therapy or in vitro conditioning with interferon-α or interleukin-12. Am J Respir Cell Mol Biol 2001; 24:187-94.
14. Suzuki N, Kudo K, Sano Y, Ito K. Can Mycobacterium tuberculosis infection prevent asthma and other allergic disorders? Int Arch Allergy Immunol 2001; 124:113-6.
15. Lin Y, Zhang M, Hofman FM, Gong J, Barnes PF. Absence of a prominent Th2 cytokine response in human tuberculosis. Infect Immun 1996; 64:1351-6.
16. Umland SP, Razac S, Shah H, Nahrebne DK, Egan RW, Billah MM. Interleukin-5 mRNA stability in human T cells is regulated differently than interleukin-2, interleukin-3, interleukin-4, granulocyte/macrophage colony-stimulating factor, and interferon-γ. Am J Respir Cell Mol Biol 1998; 18:631-42.
17. Druilhe P, Hagan P, Rook GA. The importance of models of infection in the study of disease resistance. Trends Microbiol 2002; 10(Suppl 10):S38-46.
18. Hernández-Pando R, Orozco H, Sampieri A, et al. Correlation between the kinetics of Th1/Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis. Immunology 1996; 89:26-33.
19. Hernández-Pando R, Orozco H, Arriaga K, Sampieri A, Larriva SJ, Madrid MV. Analysis of the local kinetics and localisation of interleukin 1α, tumour necrosis factor a and transforming growth factor β during the course of experimental pulmonary tuberculosis. Immunology 1997; 90:607-17.
20. North RJ. Mice incapable of making IL-4 or IL-10 display normal resistance to infection with Mycobacterium tuberculosis. Clin Exp Immunol 1998; 113:55-8.
21. Wangoo A, Sparer T, Brown IN, et al. Contribution of Th1 and Th2 cells to protection and pathology in experimental models of granulomatous lung disease. J Immunol 2001; 166:3432-9.
22. Lindblad EB, Elhay MJ, Silva R, Appelberg R, Andersen P. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect Immun 1997; 65:623-9.
23. Hernández-Pando R, Pavon L, Arriaga K, Orozco H, Madrid-Marina V, Rook GAW. Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte. Infect Immun 1997; 65:3317-27.
24. Hernández-Pando R, Aguilar D, Garcia Hernandez ML, Orozco H, Rook GAW. Pulmonary tuberculosis in BALB/c mice with non-functional IL-4 genes: changes in the inflammatory effects of TNF-α in the regulation of fibrosis. Eur J Immunol 2004; 34:174-83.
25. Rook GAW, Hernández-Pando R, Dheda K, Seah GT. IL-4 in tuberculosis: implications for vaccine design. Trends Immunol 2004; 25:483-8.
26. Hernández-Pando R, de la Luz Streber M, Orozco H, et al. Emergent therapeutic properties of a combination of glucocorticoid and antiglucocorticoid steroids in tuberculous BALB/c mice. QJM 1998; 91:755-66.
27. Hernández-Pando R, de la Luz Streber M, Orozco H, et al. The effects of androstenediol and dehydroepiandrosterone on the course and cytokine profile of tuberculosis in BALB/c mice. Immunology 1998; 95:234-11.
28. Hernández-Pando R, Pavon L, Orozco EH, Rangel J, Rook GAW. Interactions between hormone-mediated and vaccine-mediated immunotherapy for pulmonary tuberculosis in BALB/c mice. Immunology 2000; 100:391-8.
29. Loria RM. Immune up-regulation and tumor apoptosis by androstene steroids. Steroids 2002; 67:953-66.
30. Hernández-Pando R, Rook GAW. The role of TNF-α in T cell-mediated inflammation depends on the Th1/Th2 cytokine balance. Immunology 1994; 82:591-5.
31. Jarnagin JL, Luchsinger DW. The use of fluorescein diacetate and ethidium bromide as a stain for evaluating viability of mycobacteria. Stain Technol 1980; 55:253-8.
32. Bogdan C, Vodovotz Y, Paik J, Xie QW, Nathan C. Mechanism of suppression of nitric oxide synthase expression by interleukin-4 in primary mouse macrophages. J Leukoc Biol 1994; 55:227-33.
33. Jouanguy E, Altare F, Lamhamedi S, et al. Interferon-γ receptor deficiency in an infant with fatal bacille Calmette-Guérin infection. N Engl J Med 1996; 335:1956-61.
34. Meikle AW, Dorchuck RW, Araneo BA, et al. The presence of a dehydroepiandrosterone-specific receptor binding complex in murine T cells. J Steroid Biochem Mol Biol 1992; 42:293-304.
35. Okabe T, Haji M, Takayanagi R, et al. Up-regulation of high-affinity dehydroepiandrosterone binding activity by dehydroepiandrosterone in activated human T lymphocytes. J Clin Endocrinol Metab 1995; 80:2993-6.
36. Ripp SL, Fitzpatrick JL, Peters JM, Prough RA. Induction of CYP3A expression by dehydroepiandrosterone: involvement of the pregnane X receptor. Drug Metab Dispos 2002; 30:570-5.
37. Prough RA, Webb SJ, Wu HQ, Lapenson DP, Waxman DJ. Induction of microsomal and peroxisomal enzymes by dehydroepiandrosterone and its reduced metabolite in rats. Cancer Res 1994; 54:2878-86.
38. Dashtaki R, Whorton AR, Murphy TM, Chitano P, Reed W, Kennedy TP. Dehydroepiandrosterone and analogs inhibit DNA binding of AP-1 and airway smooth muscle proliferation. J Pharmacol Exp Ther 1998; 285:876-83.
39. Herrlich P. Cross-talk between glucocorticoid receptor and AP-1. Oncogene 2001; 20:2465-75.
40. Frincke J, Onizuka-Handa N, Stickney D, Ahlem C, Reading C. Treatment naive HIV-1-infected patients respond immunologically when administered HE2000: results from a phase I/II trial. In: Program and abstracts of the 13th International Conference on Antiviral Research (Baltimore). International Society for Antiviral Research, 2000.